Developer docs
API playgroundTry for free, no card

Search company profiles

HEMO BIOENGINEERING

Full company profile

uuid000dzzx

Namestring
HEMO BIOENGINEERING
Legal namestring
HEMO BIOENGINEERING LIMITED
Websiteurl
hemocorp.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

HEMO BIOENGINEERING LIMITED is a Singapore-based, privately-held medical device company founded in 2017 that develops and commercializes interventional devices for neurovascular and peripheral vascular diseases. The company was founded by Professor Jack Wang, former CEO of SGX Mainboard-listed Biosensors International Group and JW Medical Systems, and is headquartered in Singapore with R&D in the United States and manufacturing operations in China and Malaysia. As of the latest reporting, the company has 51-100 employees and has raised approximately US$138.5 million in venture funding across Series A through Series C rounds between 2017 and 2020.

The company's product portfolio spans three categories: mechanical thrombectomy devices (AsprAX Aspiration Catheter and CerebrAX Stent Retriever System, both CE MDR approved; Afentta Aspiration Catheter, China's first domestically-produced aspiration catheter system with NMPA approval); neuro access and dilation devices (EmerAX Access Catheter, FlexStar Balloon Guiding Catheter, Mountix Micro Catheter, FocuStar Neuro Balloon Catheter, Bonpass Intracranial Balloon Dilation Catheter); and peripheral vascular products (FocusLine PTA Balloon Dilation Catheter, Instalief hemorrhoid device). Proprietary catheter design elements include novel braiding techniques, ultra-soft and ultra-thin profiles, and larger inner lumen relative to peers at same outer diameter. Key regulatory milestones include NMPA approvals for multiple devices in China, CE MDR approvals in 2023, EN ISO 13485:2016 certification, and Class 10K Cleanroom certification.

The business model is B2B enterprise hardware sales, with products sold directly to hospitals, stroke centers, and neurointerventionalists and through international distribution partners across Europe, Asia, and the Middle East. The company also generates revenue through OEM manufacturing services for medical devices and a regulatory and market access partnership service that helps third-party medical device companies enter nine Southeast Asian markets. Pricing is negotiated enterprise-by-enterprise and not publicly disclosed. Distribution channels include direct hospital sales, international distribution partners across Europe, Asia, and the Middle East, and a Southeast Asia regulatory services network. The company maintains thought leadership through LinkedIn, educational stroke-awareness website content, and participation in medical conferences including CSA and TISC.

Short descriptiontext

HEMO BIOENGINEERING is a Singapore-based medical device company that develops and commercializes CE MDR and NMPA approved interventional catheters for mechanical thrombectomy, neurovascular access, and peripheral vascular procedures, selling to hospitals and stroke centers across Asia, Europe, and the Middle East.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices12 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
interventional medical devices, neurovascular devices, mechanical thrombectomy, aspiration catheters, peripheral vascular catheters
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurovascular Interventional Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of neurovascular and peripheral vascular interventional medical devices including aspiration catheters, stent retrievers, access catheters, balloon dilation catheters, and micro catheters to hospitals and healthcare institutions.

hemocorp.com
2OEM Services
TypeHardware Sales
Description

Original equipment manufacturing services for medical devices.

hemocorp.com
3Regulatory and Market Access Services
TypeProfessional Services
Description

Regulatory and market access partnership strategic services for medical device companies desiring to venture into different markets in Southeast Asia. Services include product registration, license procurement, post-market compliance, importation, customs clearance, and distribution support.

hemocorp.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1FocusLine
Description

PTA balloon dilation catheter product line for peripheral vascular interventions.

hemocorp.com
+9 more records
Core offering1 text field

HEMO BIOENGINEERING develops, manufactures, and commercializes a portfolio of interventional medical devices for neurovascular and peripheral vascular diseases, including mechanical thrombectomy devices (aspiration catheters and stent retrievers), access and guiding catheters, neuro and peripheral balloon dilation catheters, and a hemorrhoid treatment device. The company sells these devices to hospitals, stroke centers, and neurointerventionalists, and provides OEM manufacturing and regulatory/market access partnership services for Southeast Asia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Achieved recanalization rates of 80-90% in clinical studies
+2 more records
Product overview1 text field

HEMO BIOENGINEERING is a medical device company developing innovative interventional medical devices for neurovascular and peripheral diseases. The product portfolio consists of three main categories: (1) Mechanical Thrombectomy Devices including AsprAX Aspiration Catheter, CerebrAX Stent Retriever System, and Afentta Aspiration Catheter for acute ischemic stroke treatment; (2) Neuro Access and Dilation Devices including EmerAX Access Catheter, FlexStar Balloon Guiding Catheter, Mountix Micro Catheter, FocuStar Neuro Dilation Catheter (Rx), and Bonpass Neuro Dilation Catheter (OTW) for neuro-interventional procedures; and (3) Peripheral Products including Instalief (hemorrhoid treatment device) and FocusLine PTA Balloon Dilation Catheter for peripheral vascular procedures. The company also provides OEM manufacturing services and regulatory/market access partnership services for medical device companies entering Southeast Asian markets.

Product and service12 records
1AsprAX Aspiration Catheter
CategoryMechanical Thrombectomy Devices
Description

CE MDR approved flagship aspiration catheter for mechanical thrombectomy treatment of acute ischemic stroke. Features large inner lumen for greater aspiration force, comprehensive sizes (0.035" to 0.088") and lengths (100cm to 158cm), soft distal tip with strong proximal end for enhanced navigability, superior pushability with kink prevention, and proprietary braiding technique.

2CerebrAX Stent Retriever System
CategoryMechanical Thrombectomy Devices
Description

CE MDR approved self-expanding stent retriever for mechanical thrombectomy in acute ischemic stroke. Available in 3mm, 4mm, 5mm and 6mm diameters, with multiple radiopaque markers for visibility, strong nitinol alloy construction, and softer atraumatic stent design for vessel safety.

3Afentta Aspiration Catheter
CategoryMechanical Thrombectomy Devices
Description

NMPA approved intracranial thrombectomy aspiration catheter developed by HEMO BIOENGINEERING (CHINA) LTD, China's first domestically-produced aspiration catheter system. Uses proprietary technologies for direct aspiration treatment of acute ischemic stroke with demonstrated shorter procedure times, higher recanalization rates, lower disability rates, and lower incidence of arterial dissection.

4EmerAX Access Catheter
CategoryAccess Devices
Description

Intermediate access catheter for neuro-interventional procedures in treatment of acute ischemic stroke, intracranial atherosclerosis, and hemorrhagic stroke. Single lumen, braid- and coil-reinforced variable stiffness catheter with smooth transitioning, ultra-soft tip, good kink-resistance, trackability, and shape memory. Sizes range from 0.055" to 0.088" inner diameter and 80cm to 132cm effective length.

5FlexStar Balloon Guiding Catheter
CategoryAccess Devices
Description

Balloon guiding catheter that effectively dissuades blood flow while exerting negative pressure aspiration or creating an arteriovenous short circuit to reverse direction of blood flow. Designed for neuro-interventional therapy applications.

6Mountix Micro Catheter
CategoryAccess Devices
Description

Micro catheter with gradient design for effective transmission of push force and torque control to reach awkward positions in tortuous vasculature. Features smooth and seamless pushability with exclusive hydrophilic coating formula to reduce surface friction.

7FocuStar Neuro Dilation Catheter (Rx)
CategoryDilation Devices
Description

Latest generation rapid-exchange neuro dilation catheter for treatment of intracranial stenosis. Features dual radiopaque markers for balloon location monitoring under X-ray, smooth surface coating for improved pushability, ultra-thin wall for flexibility and pressure-resistance, and short soft thin tip for navigating tortuous vessels.

8Bonpass Neuro Dilation Catheter (OTW)
CategoryDilation Devices
Description

Over-the-wire intracranial balloon dilation catheter designed to lower pressure while effectively enhancing safety. Coaxial design improves tractability towards lesion with better performance through tortuous vessels, intended for treatment of intracranial stenosis.

9FocusLine PTA Balloon Dilation Catheter
CategoryPeripheral Vascular Devices
Description

Proprietary, self-developed and self-manufactured percutaneous transluminal angioplasty (PTA) balloon dilation catheter for peripheral interventional procedures. Features inflatable balloon at tip used in minimally invasive catheterization procedures to enlarge narrowed vessel openings.

10Instalief Hemorrhoid Treatment Device
CategoryPeripheral Products
Description

Hand-held device providing effective physical relief of hemorrhoidal symptoms. Features a cooling balloon that directly applies pressure onto hemorrhoids to stem bleeding while low temperatures alleviate pain and discomfort.

11OEM Manufacturing Services for Medical Devices
CategoryManufacturing Services
Description

Original Equipment Manufacturing (OEM) services for medical devices, leveraging HEMO's Class 10K Cleanroom certified manufacturing operations across Singapore, Malaysia and China.

12Regulatory and Market Access Partnership Service
CategoryRegulatory and Market Access Services
Description

Strategic regulatory and market access services for medical device companies seeking to enter Southeast Asian markets. Includes autonomous license holding, product registration, license procurement, post-market compliance, importation, customs clearance, and distribution support across Singapore, Vietnam, Thailand, Philippines, Indonesia, Malaysia, Hong Kong, Taiwan, and India.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Technology Licensors
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-01-01
Description

In-licensed technologies for aspiration catheter and access catheter during early company formation.

hemocorp.com
2Key Opinion Leaders and Industry Experts
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Network of key opinion leaders and industry experts supporting product development, clinical studies, and medical education.

hemocorp.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic (via the legacy Covidien Solitaire stent retriever and neurovascular portfolio) competes head-to-head with HEMO's stent retrievers and access catheters in acute ischemic stroke and intracranial interventions.

TypeDirect peer
Description

Penumbra is the global leader in aspiration-based mechanical thrombectomy (Penumbra System / RED reperfusion catheters), directly competing with HEMO's AsprAX and Afentta aspiration catheters in acute ischemic stroke treatment across hospitals and stroke centers.

TypeBroad incumbent
Description

Stryker's Neurovascular division (Trevo stent retriever, acquired Concentric Medical) is a major incumbent in mechanical thrombectomy and intracranial access — the same product categories where HEMO positions CerebrAX and EmerAX.

TypeBroad incumbent
Description

Cerenovus (J&J MedTech) sells the Embotrap stent retriever and a broad neurovascular portfolio that overlaps directly with HEMO's mechanical thrombectomy and access device lines in major stroke centers.

TypeEmerging player
Description

Acandis develops stent retrievers and intracranial implant systems for mechanical thrombectomy and aneurysm treatment, competing in the same European neuro-interventional market where HEMO entered in 2023.

TypeEmerging player
Description

Perflow Medical develops braided net-based stent retrievers and neurovascular devices, targeting the same acute ischemic stroke indication as HEMO's CerebrAX and AsprAX platforms.

TypeRegional player
Description

Balt is a France-based neurovascular company with a broad portfolio of microcatheters, guide catheters and embolization devices used in European stroke and aneurysm centers, with overlapping technology to HEMO's access and micro-catheter range.

TypeEmerging player
Description

Rapid Medical develops stent retrievers (TigerTriever) and adjustable neurovascular devices focused on ischemic and hemorrhagic stroke — a niche, high-growth competitor in the same procedure categories HEMO targets.

TypeEmerging player
Description

Phenox is a Germany-based specialist in stent retrievers, flow diverters and intracranial access devices, selling into European and international stroke centers — overlapping with HEMO's CE MDR–targeted product portfolio.

10MicroPort Scientific (微创医疗)
TypeEmerging player
Description

MicroPort's neurovascular subsidiary sells aspiration catheters and intracranial access devices in China and globally, making it one of the closest comparable Chinese neurovascular device players to HEMO BIOENGINEERING (CHINA) LTD.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HEMO BIOENGINEERING

Neurovascular Interventional Medical Deviceshemocorp.com

HEMO BIOENGINEERING is a Singapore-based medical device company that develops and commercializes CE MDR and NMPA approved interventional catheters for mechanical thrombectomy, neurovascular access, and peripheral vascular procedures, selling to hospitals and stroke centers across Asia, Europe, and the Middle East.

What HEMO BIOENGINEERING does

HEMO BIOENGINEERING LIMITED is a Singapore-based, privately-held medical device company founded in 2017 that develops and commercializes interventional devices for neurovascular and peripheral vascular diseases. The company was founded by Professor Jack Wang, former CEO of SGX Mainboard-listed Biosensors International Group and JW Medical Systems, and is headquartered in Singapore with R&D in the United States and manufacturing operations in China and Malaysia. As of the latest reporting, the company has 51-100 employees and has raised approximately US$138.5 million in venture funding across Series A through Series C rounds between 2017 and 2020.

The company's product portfolio spans three categories: mechanical thrombectomy devices (AsprAX Aspiration Catheter and CerebrAX Stent Retriever System, both CE MDR approved; Afentta Aspiration Catheter, China's first domestically-produced aspiration catheter system with NMPA approval); neuro access and dilation devices (EmerAX Access Catheter, FlexStar Balloon Guiding Catheter, Mountix Micro Catheter, FocuStar Neuro Balloon Catheter, Bonpass Intracranial Balloon Dilation Catheter); and peripheral vascular products (FocusLine PTA Balloon Dilation Catheter, Instalief hemorrhoid device). Proprietary catheter design elements include novel braiding techniques, ultra-soft and ultra-thin profiles, and larger inner lumen relative to peers at same outer diameter. Key regulatory milestones include NMPA approvals for multiple devices in China, CE MDR approvals in 2023, EN ISO 13485:2016 certification, and Class 10K Cleanroom certification.

The business model is B2B enterprise hardware sales, with products sold directly to hospitals, stroke centers, and neurointerventionalists and through international distribution partners across Europe, Asia, and the Middle East. The company also generates revenue through OEM manufacturing services for medical devices and a regulatory and market access partnership service that helps third-party medical device companies enter nine Southeast Asian markets. Pricing is negotiated enterprise-by-enterprise and not publicly disclosed. Distribution channels include direct hospital sales, international distribution partners across Europe, Asia, and the Middle East, and a Southeast Asia regulatory services network. The company maintains thought leadership through LinkedIn, educational stroke-awareness website content, and participation in medical conferences including CSA and TISC.

HEMO BIOENGINEERING firmographics

Firmographics
Name
HEMO BIOENGINEERING
Legal name
HEMO BIOENGINEERING LIMITED
Website
https://hemocorp.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
HEMO BIOENGINEERING is a Singapore-based medical device company that develops and commercializes CE MDR and NMPA approved interventional catheters for mechanical thrombectomy, neurovascular access, and peripheral vascular procedures, selling to hospitals and stroke centers across Asia, Europe, and the Middle East.
Ownership category
akta.pro rank

HEMO BIOENGINEERING industry classification

Industry
Product category
Neurovascular Interventional Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Interventional medical devices
  • Neurovascular devices
  • Mechanical thrombectomy
  • Aspiration catheters
  • Peripheral vascular catheters

Where HEMO BIOENGINEERING is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices12 records

Markets served

HEMO BIOENGINEERING business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Sale of neurovascular and peripheral vascular interventional medical devices including aspiration catheters, stent retrievers, access catheters, balloon dilation catheters, and micro catheters to hospitals and healthcare institutions.
  2. OEM Services: Original equipment manufacturing services for medical devices.
  3. Regulatory and Market Access Services: Regulatory and market access partnership strategic services for medical device companies desiring to venture into different markets in Southeast Asia. Services include product registration, license procurement, post-market compliance, importation, customs clearance, and distribution support.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

HEMO BIOENGINEERING product offering

Product offering

Core offering

HEMO BIOENGINEERING develops, manufactures, and commercializes a portfolio of interventional medical devices for neurovascular and peripheral vascular diseases, including mechanical thrombectomy devices (aspiration catheters and stent retrievers), access and guiding catheters, neuro and peripheral balloon dilation catheters, and a hemorrhoid treatment device. The company sells these devices to hospitals, stroke centers, and neurointerventionalists, and provides OEM manufacturing and regulatory/market access partnership services for Southeast Asia.

Product overview

HEMO BIOENGINEERING is a medical device company developing innovative interventional medical devices for neurovascular and peripheral diseases. The product portfolio consists of three main categories: (1) Mechanical Thrombectomy Devices including AsprAX Aspiration Catheter, CerebrAX Stent Retriever System, and Afentta Aspiration Catheter for acute ischemic stroke treatment; (2) Neuro Access and Dilation Devices including EmerAX Access Catheter, FlexStar Balloon Guiding Catheter, Mountix Micro Catheter, FocuStar Neuro Dilation Catheter (Rx), and Bonpass Neuro Dilation Catheter (OTW) for neuro-interventional procedures; and (3) Peripheral Products including Instalief (hemorrhoid treatment device) and FocusLine PTA Balloon Dilation Catheter for peripheral vascular procedures. The company also provides OEM manufacturing services and regulatory/market access partnership services for medical device companies entering Southeast Asian markets.

Differentiator

Problem solved

Functional benefit

Brands

  • FocusLine: PTA balloon dilation catheter product line for peripheral vascular interventions.
  • Afentta
  • FocuStar
  • AsprAX
  • CerebrAX
  • EmerAX
  • FlexStar
  • Mountix
  • Bonpass
  • Instalief

Products and services

  • AsprAX Aspiration Catheter CE MDR approved flagship aspiration catheter for mechanical thrombectomy treatment of acute ischemic stroke. Features large inner lumen for greater aspiration force, comprehensive sizes (0.035" to 0.088") and lengths (100cm to 158cm), soft distal tip with strong proximal end for enhanced navigability, superior pushability with kink prevention, and proprietary braiding technique.
  • CerebrAX Stent Retriever System CE MDR approved self-expanding stent retriever for mechanical thrombectomy in acute ischemic stroke. Available in 3mm, 4mm, 5mm and 6mm diameters, with multiple radiopaque markers for visibility, strong nitinol alloy construction, and softer atraumatic stent design for vessel safety.
  • Afentta Aspiration Catheter NMPA approved intracranial thrombectomy aspiration catheter developed by HEMO BIOENGINEERING (CHINA) LTD, China's first domestically-produced aspiration catheter system. Uses proprietary technologies for direct aspiration treatment of acute ischemic stroke with demonstrated shorter procedure times, higher recanalization rates, lower disability rates, and lower incidence of arterial dissection.
  • EmerAX Access Catheter Intermediate access catheter for neuro-interventional procedures in treatment of acute ischemic stroke, intracranial atherosclerosis, and hemorrhagic stroke. Single lumen, braid- and coil-reinforced variable stiffness catheter with smooth transitioning, ultra-soft tip, good kink-resistance, trackability, and shape memory. Sizes range from 0.055" to 0.088" inner diameter and 80cm to 132cm effective length.
  • FlexStar Balloon Guiding Catheter Balloon guiding catheter that effectively dissuades blood flow while exerting negative pressure aspiration or creating an arteriovenous short circuit to reverse direction of blood flow. Designed for neuro-interventional therapy applications.
  • Mountix Micro Catheter Micro catheter with gradient design for effective transmission of push force and torque control to reach awkward positions in tortuous vasculature. Features smooth and seamless pushability with exclusive hydrophilic coating formula to reduce surface friction.
  • FocuStar Neuro Dilation Catheter (Rx) Latest generation rapid-exchange neuro dilation catheter for treatment of intracranial stenosis. Features dual radiopaque markers for balloon location monitoring under X-ray, smooth surface coating for improved pushability, ultra-thin wall for flexibility and pressure-resistance, and short soft thin tip for navigating tortuous vessels.
  • Bonpass Neuro Dilation Catheter (OTW) Over-the-wire intracranial balloon dilation catheter designed to lower pressure while effectively enhancing safety. Coaxial design improves tractability towards lesion with better performance through tortuous vessels, intended for treatment of intracranial stenosis.
  • FocusLine PTA Balloon Dilation Catheter Proprietary, self-developed and self-manufactured percutaneous transluminal angioplasty (PTA) balloon dilation catheter for peripheral interventional procedures. Features inflatable balloon at tip used in minimally invasive catheterization procedures to enlarge narrowed vessel openings.
  • Instalief Hemorrhoid Treatment Device Hand-held device providing effective physical relief of hemorrhoidal symptoms. Features a cooling balloon that directly applies pressure onto hemorrhoids to stem bleeding while low temperatures alleviate pain and discomfort.
  • OEM Manufacturing Services for Medical Devices Original Equipment Manufacturing (OEM) services for medical devices, leveraging HEMO's Class 10K Cleanroom certified manufacturing operations across Singapore, Malaysia and China.
  • Regulatory and Market Access Partnership Service Strategic regulatory and market access services for medical device companies seeking to enter Southeast Asian markets. Includes autonomous license holding, product registration, license procurement, post-market compliance, importation, customs clearance, and distribution support across Singapore, Vietnam, Thailand, Philippines, Indonesia, Malaysia, Hong Kong, Taiwan, and India.

Quantifiable outcome

  • Achieved recanalization rates of 80-90% in clinical studies
  • +2 more outcomes

Companies that use HEMO BIOENGINEERING

Customer profile

Segments4 records

Ideal customer profiles2 records

HEMO BIOENGINEERING technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

HEMO BIOENGINEERING partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and strategic.

  • Technology LicensorscoreTechnology or Integration · 1 January 2017In-licensed technologies for aspiration catheter and access catheter during early company formation.
  • Key Opinion Leaders and Industry ExpertsstrategicStrategic or Co-development PartnerNetwork of key opinion leaders and industry experts supporting product development, clinical studies, and medical education.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

HEMO BIOENGINEERING competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic (via the legacy Covidien Solitaire stent retriever and neurovascular portfolio) competes head-to-head with HEMO's stent retrievers and access catheters in acute ischemic stroke and intracranial interventions.
  • Stryker (Neurovascular): Stryker's Neurovascular division (Trevo stent retriever, acquired Concentric Medical) is a major incumbent in mechanical thrombectomy and intracranial access — the same product categories where HEMO positions CerebrAX and EmerAX.
  • Johnson & Johnson (Cerenovus): Cerenovus (J&J MedTech) sells the Embotrap stent retriever and a broad neurovascular portfolio that overlaps directly with HEMO's mechanical thrombectomy and access device lines in major stroke centers.

Direct peers

  • Penumbra: Penumbra is the global leader in aspiration-based mechanical thrombectomy (Penumbra System / RED reperfusion catheters), directly competing with HEMO's AsprAX and Afentta aspiration catheters in acute ischemic stroke treatment across hospitals and stroke centers.

Emerging players

  • Acandis: Acandis develops stent retrievers and intracranial implant systems for mechanical thrombectomy and aneurysm treatment, competing in the same European neuro-interventional market where HEMO entered in 2023.
  • Perflow Medical: Perflow Medical develops braided net-based stent retrievers and neurovascular devices, targeting the same acute ischemic stroke indication as HEMO's CerebrAX and AsprAX platforms.
  • Rapid Medical: Rapid Medical develops stent retrievers (TigerTriever) and adjustable neurovascular devices focused on ischemic and hemorrhagic stroke — a niche, high-growth competitor in the same procedure categories HEMO targets.
  • Phenox: Phenox is a Germany-based specialist in stent retrievers, flow diverters and intracranial access devices, selling into European and international stroke centers — overlapping with HEMO's CE MDR–targeted product portfolio.
  • MicroPort Scientific (微创医疗): MicroPort's neurovascular subsidiary sells aspiration catheters and intracranial access devices in China and globally, making it one of the closest comparable Chinese neurovascular device players to HEMO BIOENGINEERING (CHINA) LTD.

Regional players

  • Balt: Balt is a France-based neurovascular company with a broad portfolio of microcatheters, guide catheters and embolization devices used in European stroke and aneurysm centers, with overlapping technology to HEMO's access and micro-catheter range.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

HEMO BIOENGINEERING social profiles

Digital presence

HEMO BIOENGINEERING compliance and trust

Trust signal

Compliance4 records

HEMO BIOENGINEERING financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HEMO BIOENGINEERING leadership team

Management profile

Number of profiles

Profiles2 records

HEMO BIOENGINEERING subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

HEMO BIOENGINEERING funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HEMO BIOENGINEERING M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEMO BIOENGINEERING

What does HEMO BIOENGINEERING do?

HEMO BIOENGINEERING develops, manufactures, and commercializes a portfolio of interventional medical devices for neurovascular and peripheral vascular diseases, including mechanical thrombectomy devices (aspiration catheters and stent retrievers), access and guiding catheters, neuro and peripheral balloon dilation catheters, and a hemorrhoid treatment device. The company sells these devices to hospitals, stroke centers, and neurointerventionalists, and provides OEM manufacturing and regulatory/market access partnership services for Southeast Asia.

Is HEMO BIOENGINEERING a public or private company?

HEMO BIOENGINEERING is a private company. It is classified as venture growth investor backed and is currently operating.

When was HEMO BIOENGINEERING founded?

HEMO BIOENGINEERING was founded in 2017. It employs 11 to 50 people.

Where is HEMO BIOENGINEERING based?

HEMO BIOENGINEERING is headquartered in Singapore, Singapore, in the Asia region.

How does HEMO BIOENGINEERING make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are OEM Services and regulatory and Market Access Services.

Who are HEMO BIOENGINEERING's main competitors?

Broad incumbents on record are Medtronic, Stryker (Neurovascular) and Johnson & Johnson (Cerenovus). Penumbra is listed as a direct peer. Emerging players are Acandis, Perflow Medical, Rapid Medical, Phenox and MicroPort Scientific (微创医疗). Balt is listed as a regional player.

Does HEMO BIOENGINEERING have an API?

No public API is recorded for HEMO BIOENGINEERING.

What industry is HEMO BIOENGINEERING in?

HEMO BIOENGINEERING's product category is Neurovascular Interventional Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals